Noveris Health Sciences Inc. has joined Life Sciences British Columbia, a key industry association supporting the province's life sciences community. This membership aims to enhance Noveris' visibility, foster collaboration, and expand networking opportunities with innovators, investors, and partners in British Columbia. The company expects to benefit from LSBC's programming and initiatives to support its strategic development and commercialization goals in healthcare technology. This move reflects Noveris' commitment to active participation in the local and national biotech ecosystem.
Analysts have raised their price targets for Cheniere Energy, signaling confidence in the company's future growth. Argus increased its target to $330, suggesting a 20.33% upside from the current price of around $274. TD Cowen also raised its target t...
KeyBanc and DA Davidson upgraded Duolingo's stock rating, citing positive sentiment and raising price targets to $137.11 and $160 respectively. This upgrade lifted Duolingo shares by 4.3% in pre-market trading to $135.71. Despite this optimism, most ...
ReNew Energy Global exceeded analyst expectations in Q1 FY2027 by reporting EPS of $0.17 versus $0.12 estimated and revenue of $506.4 million, surpassing the $459.86 million forecast. The company expanded its renewable energy portfolio to about 20.5 ...
Jack Henry & Associates is expected to report Q2 earnings with an EPS of $1.47 and revenue of $631.6 million. Analysts note the company has a strong record of beating earnings estimates, with an average surprise of nearly 20% in recent quarters. Fina...
Argenx reported successful Phase 3 clinical trial results for its drug VYVGART Hytrulo, targeting autoimmune myositis, especially benefiting patients with IMNM who lack approved therapies. The trial met its primary endpoint with statistically signifi...
